Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERNA-101
- Development stage
- Preclinical
- Lead developer
- Ernexa Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraperitoneal, Intratumoral
01
Overview
**ERNA-101** is an investigational, allogeneic, off-the-shelf induced mesenchymal stromal cell therapy developed by Ernexa Therapeutics for platinum-resistant ovarian cancer. The product consists of induced mesenchymal stromal cells derived from induced pluripotent stem cells and engineered to home to tumor tissue and deliver an IL-7/IL-15 fusion cytokine in the tumor microenvironment. Local cytokine delivery is intended to activate and expand T cells and natural killer cells, enhance immune-cell infiltration, promote a pro-inflammatory antitumor microenvironment, and convert immunologically \"cold\" tumors into \"hot\" tumors. ERNA-101 remains in preclinical and IND-enabling development, with an IND submission planned for the third quarter of 2026 and a first-in-human study planned thereafter.
- Other names
- iMSC-IL7/IL15iMSCs engineered to secrete IL-7 and IL-15iPSC-derived MSC-IL7/IL15
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on ERNA-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERNA-101.